NasdaqGM:TVTXBiotechs
A Look At Travere Therapeutics (TVTX) Valuation After New Long Term FILSPARI FSGS Data
Travere Therapeutics (TVTX) is back in focus after new long term data from its Phase 3 DUPLEX Study open label extension showed sustained, clinically meaningful proteinuria reductions in focal segmental glomerulosclerosis patients on FILSPARI.
See our latest analysis for Travere Therapeutics.
The latest DUPLEX data and recent licensing moves have arrived after a powerful run, with Travere’s share price up 58.07% over 90 days and a 1 year total shareholder return close to 3x, although short...